Compare SoFi Technologies Inc (SOFI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs TG Therapeutics Inc — how do they compare? SoFi Technologies Inc trades at $15.8 (market cap $20.16B), while TG Therapeutics Inc trades at $54.83 (market cap $8.16B). The key difference: SoFi Technologies Inc is far larger — about 2.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SoFi Technologies Inc for 60 Days and TG Therapeutics Inc for 16 Days on average.
| SOFI | TGTX | |
|---|---|---|
Market Cap | $20.16B | $8.16B |
Volume | 49,646,331 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $32.21 | $59.06 |
52-Week Low | $15.15 | $26.94 |
Typical Hold Time | 60 Days | 16 Days |
Enterprise Value | $20.30B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoFi Technologies (SOFI) trades at $15.72, up 0.38% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported strong revenue growth, with 2025 revenue reaching $3.61 billion and net income of $481.32 million, though cash flow from operations remains negative. Analyst consensus is mixed with a $21.58 price target, but technical indicators signal caution.
SoFi's growth trajectory and improving profitability present long-term potential, but near-term risks include persistent negative operating cash flow, high valuation multiples, and sensitivity to interest rates. Execution on loan originations and stablecoin initiatives will be critical for stock performance.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
